Notices. Notice

330 words·~2 min read·/register/2020/06/25/2020-13656

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4140-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing Michael Shmilovich, *shmilovm@nih.gov* , the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579.

A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: Technology description follows. Liposome Nanodecoys That Protect Against SARS-COV-2 Available for licensing and commercial development are patent rights covering a liposomal vesicle (a “nanodecoy”) with a lipid bilayer with one or more proteins recognized by a pathogen ( *e.g.,* SARS-CoV-2) and one or more cytokine receptors (such as IL-6; receptors: CD126, CD130;

IL-1; receptors: CD121a, CD121b, IL-8; receptors: IL-8RB; IL-12; receptors: CD212; TNF-α; receptors: CD120a, CD120b; IFN-γ; receptors: CD119, IFN-α/β; receptors: CD118) and wherein the liposomal vesicle is non-replicating. Nanodecoys that display angiotensin-converting enzyme 2

(ACE2)and multiple cytokine receptors, are able to sequester SARS-CoV-2 and inhibit viral replication and infection, as well as to mitigate COVID-19-induced cytokine release syndrome

(CRS)in susceptible cells. *Potential Commercial Applications:* • COVID-19 • SARS-CoV-2 • Cytokine release syndrome ○ immunosuppression • Viral inhibition ○ Receptor binding competition *Development Stage:* • Preclinical *Inventors:* Xiaoyuan (Shawn) Chen (NIBIB) and Lang Rao (NIBIB). *Intellectual Property:* HHS Reference No. E-144-2020-0-US-01 “Engineered Cell Membrane Nanodecoys To Protect Against COVID-19;” U.S. Provisional Patent Application 63/038,380 filed June 12, 2020. *Licensing Contact:* Michael Shmilovich, Esq, CLP; 301-435-5019; *shmilovm@mail.nih.gov.* Dated: June 17, 2020. Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2020-13656 Filed 6-24-20; 8:45 am]